Evidence map›Paper›PMID 37928667›Full record

ArticleFrontiers in microbiology2023

Electrolyzed hypochlorous acid water exhibits potent disinfectant activity against various viruses through irreversible protein aggregation.

Rahmi Dianty, Junki Hirano, Itsuki Anzai, Yuta Kanai, Tsuyoshi Hayashi, Masae Morimoto, Chikako Kataoka-Nakamura, Sakura Kobayashi, Kentaro Uemura, Chikako Ono and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Commercially available antiseptics show highFrontiers in veterinary science · 2025
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Rahmi DiantyLaboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan.
Junki HiranoLaboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan.
Itsuki AnzaiLaboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan.
Yuta KanaiLaboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan.
Tsuyoshi HayashiDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
Masae MorimotoInnovative Vaccine Research and Development Center, The Research Foundation for Microbial Diseases of Osaka University, Osaka, Japan.
Chikako Kataoka-NakamuraInnovative Vaccine Research and Development Center, The Research Foundation for Microbial Diseases of Osaka University, Osaka, Japan.
Sakura KobayashiDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
Kentaro UemuraLaboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan.
Chikako OnoLaboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan.
Tokiko WatanabeLaboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan.
Takeshi KobayashiLaboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan.
Kosuke MurakamiDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
Kenji KikuchiLouis Pasteur Center for Medical Research, Kyoto, Japan.
Kunimoto HottaLouis Pasteur Center for Medical Research, Kyoto, Japan.
Toshikazu YoshikawaLouis Pasteur Center for Medical Research, Kyoto, Japan.
Shuhei TaguwaLaboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan.
Yoshiharu MatsuuraLaboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan.
Osaka University · JPLouis Pasteur Center for Medical Research · JPNational Institute of Infectious Diseases · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is essential to employ efficient measures to prevent the transmission of pathogenic agents during a pandemic. One such method involves using hypochlorous acid (HClO) solution. The oxidative properties of HClO water (HAW) can contribute to its ability to eliminate viral particles. Here, we examined a highly purified slightly acidic hypochlorous acid water (Hp-SA-HAW) obtained from the reverse osmosis membrane treatment of an electrolytically-generated SA-HAW for its anti-viral activity and mode of action on viral proteins. Hp-SA-HAW exhibited broad-spectrum antiviral effects against various viruses, including adenovirus, hepatitis B virus, Japanese encephalitis virus (JEV), and rotavirus. Additionally, Hp-SA-HAW treatment dose-dependently resulted in irreversibly aggregated multimers of the JEV envelope and capsid proteins. However, Hp-SA-HAW treatment had no discernible effect on viral RNA, indicating that Hp-SA-HAW acts against amino acids rather than nucleic acids. Furthermore, Hp-SA-HAW substantially reduced the infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including the ancestral variant and other multiple variants. Hp-SA-HAW treatment induced the aggregation of the SARS-CoV-2 spike and nuclear proteins and disrupted the binding of the purified spike protein of SARS-CoV-2 to human ACE2. This study demonstrates that the broad-spectrum virucidal activity of highly purified HClO is attributed to viral protein aggregation of virion via protein oxidation.

Indexed as

hypochlorous acidoxidationprotein aggregationSARS-CoV-2virucide

Identifiers

PMID37928667
PMCPMC10625411
OpenAlexW4387779313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.